Modified NK Cells Overcoming Tumor Suppression in ADCC Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapy approaches using NK cells for treating solid tumors have seen limited success due to tumors harnessing inhibitory pathways to suppress cytotoxic NK cell activity, leading to suboptimal responses.
Innovation Solution
Modified NK cells with specific genomic edits, such as loss-of-function in TGFbetaR2 and/or CISH, and expression of CD16 variants or chimeric antigen receptors, are used in combination with therapeutic antibodies to enhance antibody-dependent cellular cytotoxicity (ADCC) against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naturally occurring or modified NK cells are used in immunotherapy approaches, then NK cell transfer can be performed, but the NK cell response is suboptimal due to tumors harnessing inhibitory pathways
Solution Approach 1:
The patent removes inhibitory pathways (such as TGF-beta signaling through TGFBR2 knockout and CISH deletion) from NK cells to eliminate the suppressive mechanisms that tumors exploit, thereby extracting the harmful elements that limit NK cell effectiveness while preserving their cytotoxic functions
Solution Approach 2:
The patent modifies NK cell parameters through genetic engineering to enhance their functional properties, including knocking out inhibitory receptors (TGFBR2, CISH), overexpressing activating receptors (CD16 variants, chimeric antigen receptors), and modifying cytokine receptors to improve survival and proliferation signals, thereby changing the cellular parameters that determine therapeutic effectiveness
2Reliability
If NK cells are modified to overcome inhibitory pathways, then cytotoxic activity can be enhanced, but the complexity of cell modification increases
Solution Approach 1:
The patent divides the complex modification strategy into separate, modular genetic edits that can be independently implemented and combined, such as individual knockout of TGFBR2, CISH, or other inhibitory pathways, and separate overexpression of different activating receptors, allowing for systematic optimization without overwhelming complexity
Solution Approach 2:
The patent employs universal modification approaches that can be applied across different NK cell sources and tumor types, such as using standardized CRISPR-Cas9 knockout protocols for inhibitory pathways and universal overexpression vectors for activating receptors, making the modification process more scalable and less complex
Data Source
AI summary
The present disclosure is directed to the use of modified NK cells for immunotherapy in combination with an antibody, or antigen-binding fragment thereof, to induce an enhanced antibody-dependent cellular cytotoxicity (ADCC) effect.